Diacerein, an anthraquinone derivative, has gained interest in recent years as a potential therapeutic agent in the management of knee osteoarthritis (KOA), particularly the inflammatory subtype effusion synovitis. This commentary evaluates the effect of diacerein on KOA symptoms and functional outcomes of recent parts of a multicenter randomized controlled trial. The clinical trial of diacerein as a monotherapy for effusion synovitis concluded that not only was there no overall significant change in the knee joint's moisture content after a 24‐week therapy but also there was no evidence of symptomatic or functional improvement. Furthermore, problems like diarrhea and colored urine raised questions about its safety and user‐friendly profile; therefore, these findings were contentious. These outcomes highlight the need for greater investigation of diacerein, including in combination therapies where its benefits are amplified and adverse effects diminished. Further research should help to define diacerein's role in KOA treatment and increase the understanding of its actions regarding effusion synovitis, focusing on side effects.

The burden of noncommunicable diseases is increasing rapidly in low‐ and middle‐income countries creating a growing need for advanced diagnostic and therapeutic modalities. Nuclear medicine offers great potential in disease detection, treatment planning, and monitoring, yet its integration into resource‐limited health systems remains challenging. This review synthesizes evidence from peer‐reviewed publications and relevant reports from international agencies to examine barriers to, and enablers of, nuclear medicine adoption in these settings. We found that key obstacles include financial constraints, restricted access to essential materials, insufficient regulatory frameworks, and shortages of skilled professionals. These gaps contribute to safety concerns, inadequate waste management, and delays in service delivery. Although global initiatives have strengthened workforce training and promoted regulatory harmonization, persistent issues in financial sustainability and retention of trained staff hinder progress. Technological advances, such as novel imaging and therapeutic approaches, present opportunities; however, their successful implementation requires context‐specific strategies that align with local infrastructure and policy realities. Integrating nuclear medicine into health systems in low‐resource environments can address multiple health care priorities simultaneously, but this will require targeted investment, sustainable financing mechanisms, and strengthened institutional capacity. Collaborative international support, coupled with locally adapted policies, could accelerate equitable access and improve patient outcomes. Expanding the role of nuclear medicine in these regions has the potential to significantly enhance health care delivery and contribute to closing the global disparity in advanced medical services.

Background: Acne vulgaris is one of the most prevalent disorders affecting 9%–10% of the global population, representing as papules, pustules, and comedones, with a pathogenesis involving increased sebum production, C. acnes colonization, and inflammation. Conventional treatments like retinoids and antibiotics often cause side effects, thus diverting attention toward probiotics as an alternative therapy. Lactobacillus probiotics, having their immunomodulatory, anti‐inflammatory, and antimicrobial properties, are useful in managing acne by reducing inflammation and oxidative stress with proved safety profile and the potential to reduce antibiotic reliance. This systematic review and meta‐analysis evaluate the efficacy of Lactobacillus‐based probiotics compared to placebo and benzoyl peroxide in reducing inflammatory lesions, non‐inflammatory lesions, and total acne lesion counts. The findings aim to clarify their therapeutic role and provide evidence on their effectiveness and safety. Objectives: This systematic review and meta‐analysis investigated the effectiveness of oral and topical Lactobacillus‐based probiotics or postbiotics, compared with placebo or benzoyl peroxide, in patients with acne vulgaris. Methods: A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted, including studies evaluating oral or topical Lactobacillus‐based probiotic or postbiotic interventions in patients with acne vulgaris. Primary outcomes were changes in inflammatory lesion counts, while secondary outcomes included non‐inflammatory and total lesion counts, skin hydration, and sebum concentration. All analyses were performed using random‐effects models with 95% confidence intervals (CI), and heterogeneity was quantified using the I ² statistic. Results: A total of five RCTs involving 332 participants were included. The pooled mean difference for non‐inflammatory lesions was −1.39 (95% CI −5.10 to 2.32, p = 0.46), for inflammatory lesions was −0.08 (95% CI −1.28 to 1.11, p = 0.89), and for total lesion counts was −9.07 (95% CI −20.71 to 2.57, p = 0.13). These results concluded that there was no significant reduction in lesion counts with Lactobacillus‐based probiotics as compared to placebo or benzoyl peroxide. Heterogeneity was moderate to low across studies. Conclusion: This meta‐analysis indicates that Lactobacillus‐based probiotics do not provide significant clinical benefits in reducing inflammatory lesions, non‐inflammatory lesions, and total acne lesion counts in Acne vulgaris patients compared to placebo or benzoyl peroxide.

Berdazimer sodium, marketed as Zelsuvmi, is an antiviral medication used to treat a viral infection called molluscum contagiosum (MC). MC is a common skin infection caused by a poxvirus, resulting in round, stiff, but painless papules in various places on the body. Zelsuvmi's antiviral activity is associated with the release of nitric oxide, which exhibits potent antiviral properties. Zelsuvmi is used topically by patients or caregivers to treat this extremely contagious viral skin infection at home or in medical facilities. On January 5, 2024, the U.S. Food and Drug Administration approved Zelsuvmi for treating this infection in target populations, including adults and patients aged 1 year and above. Other therapies for MC, such as retinoic acid, benzoyl peroxide, and cryotherapy, are quite painful, while Zelsuvmi is less painful. The purpose of this article is to highlight the clinical importance and potential benefits of Zelsuvmi in the treatment of MC worldwide.